Xiaoming Jia1, Mahboob Alam2, Yumei Ye3, Mandeep Bajaj4, Yochai Birnbaum2. 1. The Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. Xiaoming.jia@bcm.edu. 2. The Section of Cardiology, Department of Medicine, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA. 3. The Department of Biochemistry and Molecular Biology, University of Texas Medical Branch, Galveston, TX, USA. 4. Endocrinology and Diabetes Division, Department of Medicine, Baylor College of Medicine, Houston, TX, USA.
Abstract
PURPOSE: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. METHODS: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. RESULTS: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95% CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95% CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95% CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95% CI 0.76 to 0.99) also showed significance. CONCLUSION: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.
PURPOSE: The aim of this study is to examine the cardioprotective properties of Glucagon-like peptide-1 receptor agonist, a class of antihyperglycemic therapy, via meta-analysis of four recently published cardiovascular outcomes trials. METHODS: Meta-analysis was performed pooling data from the ELIXA, LEADER, SUSTAIN-6 and EXSCEL trials. A random effects model was used to generate risk ratio with 95% confidence interval for cardiovascular and safety outcomes. RESULTS: A total of 33,457 patients were included in the meta-analysis. Based on the study, GLP-1R agonists significantly reduced all-cause mortality (RR 0.89; 95% CI 0.82 to 0.96) and cardiovascular mortality (RR 0.88; 95% CI 0.80 to 0.97) when compared to placebo. When long-acting agents were analyzed alone, reduction in major adverse cardiac events (RR 0.88; 95% CI 0.81 to 0.97) and non-fatal strokes (RR 0.87; 95% CI 0.76 to 0.99) also showed significance. CONCLUSION: Overall, GLP-1R agonists appear to have cardioprotective properties likely via modification of metabolic parameters such as glycemic control, weight loss, and improvement in blood pressure. Additional studies are warranted to compare cardiovascular outcomes among the different agents.
Entities:
Keywords:
Cardiovascular outcomes; GLP-1 receptor agonist; Type 2 diabetes mellitus
Authors: Trevor Yeong; Aaron Shengting Mai; Oliver Z H Lim; Cheng Han Ng; Yip Han Chin; Phoebe Tay; Chaoxing Lin; Mark Muthiah; Chin Meng Khoo; Mayank Dalakoti; Poay-Huan Loh; Mark Chan; Tiong-Cheng Yeo; Roger Foo; Raymond Wong; Nicholas W S Chew; Weiqin Lin Journal: ESC Heart Fail Date: 2022-01-29
Authors: Thaer Idrees; Iris A Castro-Revoredo; Alexandra L Migdal; Emmelin Marie Moreno; Guillermo E Umpierrez Journal: BMJ Open Diabetes Res Care Date: 2022-07
Authors: Megan E Capozzi; Richard D DiMarchi; Matthias H Tschöp; Brian Finan; Jonathan E Campbell Journal: Endocr Rev Date: 2018-10-01 Impact factor: 19.871